Bellerophon Therapeutics, Inc.
BLPHDelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001600132
Bellerophon Therapeutics, Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Oct 16, 2023; 22 institutions reported holding it in 13F filings for Q3 2023, worth $506.6K in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in Bellerophon Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
BLPH is no longer listed, and 13F filings after Q3 2023 list far fewer holders. See Q3 2023
- Institutional holders
- 2
- −20 vs. Q3 2023
- Shares held
- 209.6K
- −1.06M (−83.5%) vs. Q3 2023
- Total value
- $6.37K
- −$500.2K (−98.7%) vs. Q3 2023
- New holders
- 0
- 0 more added
- Sold out
- 20
- 1 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BLPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 2 | $6.37K |
| Q3 2023 | 22 | $506.6K |
| Q2 2023 | 23 | $824.9K |
| Q1 2023 | 19 | $27.9M |
| Q4 2022 | 25 | $832.7K |
| Q3 2022 | 19 | $1.18M |
| Q2 2022 | 19 | $1.40M |
| Q1 2022 | 22 | $2.68M |
| Q4 2021 | 22 | $3.82M |
| Q3 2021 | 22 | $4.81M |
| Q2 2021 | 27 | $6.34M |
| Q1 2021 | 39 | $10.9M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Bellerophon Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Raymond James & Associates | 10,000 | $370 | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 199,600 | $6.00K | 0.00% | −183,578−47.9% | Reduced |
| Wells Fargo & Company | 0 | $0 | 0.00% | −180,066−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −145,810−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −127,723−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −113,911−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −95,656−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −59,499−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −42,717−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −30,127−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −30,251−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −21,500−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −15,313−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −7,135−100.0% | Sold out |
| PFS Partners, LLC | 0 | $0 | 0.00% | −6,000−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −2,100−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −1,221−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −557−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −52−100.0% | Sold out |
| Global Wealth Strategies & Associates | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| GPS Wealth Strategies Group, LLC | 0 | $0 | 0.00% | −38−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −33−100.0% | Sold out |